Prosecution Insights
Last updated: November 04, 2026

BIOMEDICAL RESEARCH S.R.L.

Technology area: Biotechnology & Pharmaceuticals

1 pending office actions • 1 art units • 1 examiners • 0 of 1 (0%) have an AI response strategy ready

Analysis

BIOMEDICAL RESEARCH S.R.L. currently has 1 pending office action within the Biotechnology & Pharmaceuticals technology area. This matter is assigned to 1 distinct examiner and is located within 1 distinct art unit. This indicates a singular focus for the company's active patent prosecution. The concentration of the portfolio into 1 pending office action suggests that the company is currently prioritizing a specific technical advancement within the biotechnology sector.

BROWE, DAVID is the busiest examiner for the portfolio, managing 1 pending office action. This examiner is responsible for the 1 pending action currently active for the company. Prosecution strategy is centered on this individual examiner's review of the pending application. Because the entire active portfolio is under the jurisdiction of 1 examiner, the company's immediate success in the patent office is tied to the specific examination standards and preferences of this official.

Written from this page's own data; every figure is computed from USPTO records and verified before publication.

Portfolio Summary

1
Total Pending OAs
0
Non-Final OAs
1
Final Rejections
0
Advisory / Quayle

Response Deadline Pressure

Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.

1
Overdue
0
Due this week
0
Due this month
0
Due in next 60 days
0
Due later

Case Difficulty Mix

Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.

1
Hard (100%)
0
Medium (0%)
0
Easy (0%)
0
Unknown (0%)

Rejection Statute Mix

BucketCases
Multi-statute (no §101)1 (100%)

Industry Mix

How the docket's pending cases split across USPTO tech-center bands.

1
Life Sciences
100% of docket
0
Information Tech
0% of docket
0
Communications
0% of docket
0
Semiconductors
0% of docket
0
Mechanical / Eng
0% of docket
0
Business / Other
0% of docket

Time-on-OA Estimate

Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.

10 h
Manual time on pending OAs
2 h
Time saved (low, 20%)
4 h
Time saved (mid, 35%)
0.1 wks
FTE-weeks freed (mid)

Top Examiners on this docket

ExaminerApps on this docketAllow rateInterview lift
BROWE, DAVID 1 26.8% +27.8%

Hard Cases (1)

Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18248825 COMPOSITION BASED ON AUTOLOGOUS PLATELET CONCENTRATES AND A COLOSTRUM ISOLATE MIXTURE OF BIOLOGICAL FACTORS FOR USE IN THE TREATMENT OF CONDITIONS REQUIRING TISSUE REPAIR AND REGENERATION BROWE, DAVID 72d overdue

Interview Candidates (1)

Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.

App #TitleExaminerDue in
18248825 COMPOSITION BASED ON AUTOLOGOUS PLATELET CONCENTRATES AND A COLOSTRUM ISOLATE MIXTURE OF BIOLOGICAL FACTORS FOR USE IN THE TREATMENT OF CONDITIONS REQUIRING TISSUE REPAIR AND REGENERATION BROWE, DAVID 72d overdue

Top Art Units

Art UnitApps
1617 1

Pending Office Actions

App #TitleExaminerArt UnitStatutesStatusDue inAIFiled
18248825 COMPOSITION BASED ON AUTOLOGOUS PLATELET CONCENTRATES AND A COLOSTRUM ISOLATE MIXTURE OF BIOLOGICAL FACTORS FOR USE IN THE TREATMENT OF CONDITIONS REQUIRING TISSUE REPAIR AND REGENERATION BROWE, DAVID 1617 §103§112 Final Rejection 72d overdue Pending Apr 12, 2023

Managing BIOMEDICAL RESEARCH S.R.L.'s Patent Portfolio?

IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.

Start Free Trial

Frequently Asked Questions

How many pending USPTO office actions does BIOMEDICAL RESEARCH S.R.L. have?

BIOMEDICAL RESEARCH S.R.L. has 1 pending office actions as of November 2026, spread across 1 art units and 1 examiners.

Which USPTO examiner handles the most BIOMEDICAL RESEARCH S.R.L. applications?

David Browe has the most, with 1 of BIOMEDICAL RESEARCH S.R.L.'s pending office actions.

What technology area are BIOMEDICAL RESEARCH S.R.L.'s patent applications in?

Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month